Monopar Therapeutics Inc
NASDAQ:MNPR
Monopar Therapeutics Inc
NASDAQ:MNPR
Price:
56.21
USD
-2.94%
Market Cap:
$376m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
US |
|
Canadian Silver Hunter Inc
XTSX:AGH.H
|
CA |
|
E
|
EPIC Suisse AG
SIX:EPIC
|
CH |
Balance Sheet
Balance Sheet Decomposition
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Balance Sheet Decomposition is not available for
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Balance Sheet
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
2
|
9
|
7
|
13
|
17
|
20
|
8
|
7
|
46
|
62
|
|
| Cash Equivalents |
2
|
9
|
7
|
13
|
17
|
20
|
8
|
7
|
46
|
62
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
14
|
79
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
2
|
9
|
7
|
13
|
17
|
21
|
13
|
7
|
60
|
140
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
3
N/A
|
10
+242%
|
7
-26%
|
13
+82%
|
17
+26%
|
21
+22%
|
13
-36%
|
7
-44%
|
60
+721%
|
141
+133%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
0
|
0
|
1
|
1
|
2
|
3
|
2
|
2
|
3
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
0
|
0
|
0
|
1
|
1
|
2
|
3
|
2
|
5
|
3
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
0
+417%
|
0
+29%
|
1
+80%
|
1
+64%
|
2
+34%
|
3
+99%
|
2
-44%
|
5
+199%
|
3
-45%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
0
|
0
|
22
|
26
|
32
|
41
|
52
|
60
|
76
|
90
|
|
| Additional Paid In Capital |
5
|
28
|
29
|
39
|
48
|
60
|
62
|
66
|
131
|
227
|
|
| Other Equity |
2
|
18
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
3
N/A
|
10
+240%
|
7
-28%
|
13
+83%
|
16
+24%
|
19
+21%
|
10
-47%
|
6
-45%
|
55
+885%
|
138
+150%
|
|
| Total Liabilities & Equity |
3
N/A
|
10
+242%
|
7
-26%
|
13
+82%
|
17
+26%
|
21
+22%
|
13
-36%
|
7
-44%
|
60
+721%
|
141
+133%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
10
|
10
|
10
|
11
|
11
|
13
|
13
|
3
|
6
|
7
|
|
Switch to:
Switch to:
See Also
Discover More
